Highest-materiality recent filing
Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors
Board approved 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
Ratified amendment to 2018 Equity Plan: shares available increased to 20M, ISO limit to 30M.
Director Lindsay Androski resigns from Eloxx board effective August 6, 2025
Lindsay Androski notified the Board of her resignation, effective immediately on August 6, 2025.
Eloxx reprices CEO's 196,880 options to $0.0001, accelerates vesting
CEO Sumit Aggarwal holds 196,880 options with weighted avg exercise price $0.90 repriced to $0.0001.
Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M
Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.
the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board
Max materiality 0.75 · Median 0.60 · Most common event other_material